1. Home
  2. BFST vs MNKD Comparison

BFST vs MNKD Comparison

Compare BFST & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Business First Bancshares Inc.

BFST

Business First Bancshares Inc.

HOLD

Current Price

$28.39

Market Cap

948.1M

Sector

Finance

ML Signal

HOLD

Logo MannKind Corporation

MNKD

MannKind Corporation

HOLD

Current Price

$2.69

Market Cap

793.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BFST
MNKD
Founded
2006
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
948.1M
793.6M
IPO Year
2014
2004

Fundamental Metrics

Financial Performance
Metric
BFST
MNKD
Price
$28.39
$2.69
Analyst Decision
Strong Buy
Buy
Analyst Count
4
8
Target Price
$32.75
$8.56
AVG Volume (30 Days)
148.8K
3.8M
Earning Date
04-27-2026
05-08-2026
Dividend Yield
2.13%
N/A
EPS Growth
23.45
N/A
EPS
2.79
0.02
Revenue
$10,704,000.00
$348,966,000.00
Revenue This Year
$22.71
$35.81
Revenue Next Year
$5.02
$11.89
P/E Ratio
$10.09
$136.25
Revenue Growth
1.20
22.23
52 Week Low
$22.25
$2.23
52 Week High
$30.32
$6.51

Technical Indicators

Market Signals
Indicator
BFST
MNKD
Relative Strength Index (RSI) 56.88 44.63
Support Level $25.68 $2.52
Resistance Level $28.74 $6.18
Average True Range (ATR) 0.66 0.12
MACD 0.02 0.07
Stochastic Oscillator 61.75 49.11

Price Performance

Historical Comparison
BFST
MNKD

About BFST Business First Bancshares Inc.

Business First Bancshares Inc is a bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates the majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.

About MNKD MannKind Corporation

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.

Share on Social Networks: